Cargando…

Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie

Patients with schizophrenia represent a vulnerable population who have been understudied in COVID-19 research. We aimed to establish whether health outcomes and care differed between patients with schizophrenia and patients without a diagnosis of severe mental illness. We conducted a population-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Fond, Guillaume, Llorca, Pierre-Michel, Lançon, Christophe, Auquier, Pascal, Boyer, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969983/
https://www.ncbi.nlm.nih.gov/pubmed/33753948
http://dx.doi.org/10.1016/j.amp.2021.02.016
_version_ 1783666343456800768
author Fond, Guillaume
Llorca, Pierre-Michel
Lançon, Christophe
Auquier, Pascal
Boyer, Laurent
author_facet Fond, Guillaume
Llorca, Pierre-Michel
Lançon, Christophe
Auquier, Pascal
Boyer, Laurent
author_sort Fond, Guillaume
collection PubMed
description Patients with schizophrenia represent a vulnerable population who have been understudied in COVID-19 research. We aimed to establish whether health outcomes and care differed between patients with schizophrenia and patients without a diagnosis of severe mental illness. We conducted a population-based cohort study of all patients with identified COVID-19 and respiratory symptoms who were hospitalized in France between February and June 2020. Cases were patients who had a diagnosis of schizophrenia. Controls were patients who did not have a diagnosis of severe mental illness. The outcomes were in-hospital mortality and intensive care unit (ICU) admission. A total of 50,750 patients were included, of whom 823 were schizophrenia patients (1.6%). The schizophrenia patients had an increased in-hospital mortality (25.6% vs. 21.7%; adjusted odds ratio (aOR) 1.30 [95% CI 1.08–1.56], p = 0.0093) and a decreased ICU admission rate (23.7% vs. 28.4%; aOR 0.75 [95% CI 0.62–0.91], p = 0.0062) compared to controls. Significant interactions between schizophrenia and age for mortality and ICU admission were observed (p = 0.0006 and p < 0.0001). Schizophrenia patients between 65 and 80 years had a significantly higher risk of death than controls of the same age (+7.89%). schizophrenia patients younger than 55 years had more ICU admissions (+13.93%) and schizophrenia patients between 65 and 80 years and older than 80 years had less ICU admissions than controls of the same age (−15.44% and −5.93%, respectively). Our findings report the existence of disparities in health and health care between schizophrenia patients and patients without a diagnosis of severe mental illness. These disparities differed according to the age and clinical profile of schizophrenia patients, suggesting the importance of personalized COVID-19 clinical management and health care strategies before, during and after hospitalization for reducing health disparities in this vulnerable population.
format Online
Article
Text
id pubmed-7969983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-79699832021-03-18 Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie Fond, Guillaume Llorca, Pierre-Michel Lançon, Christophe Auquier, Pascal Boyer, Laurent Ann Med Psychol (Paris) Communication Patients with schizophrenia represent a vulnerable population who have been understudied in COVID-19 research. We aimed to establish whether health outcomes and care differed between patients with schizophrenia and patients without a diagnosis of severe mental illness. We conducted a population-based cohort study of all patients with identified COVID-19 and respiratory symptoms who were hospitalized in France between February and June 2020. Cases were patients who had a diagnosis of schizophrenia. Controls were patients who did not have a diagnosis of severe mental illness. The outcomes were in-hospital mortality and intensive care unit (ICU) admission. A total of 50,750 patients were included, of whom 823 were schizophrenia patients (1.6%). The schizophrenia patients had an increased in-hospital mortality (25.6% vs. 21.7%; adjusted odds ratio (aOR) 1.30 [95% CI 1.08–1.56], p = 0.0093) and a decreased ICU admission rate (23.7% vs. 28.4%; aOR 0.75 [95% CI 0.62–0.91], p = 0.0062) compared to controls. Significant interactions between schizophrenia and age for mortality and ICU admission were observed (p = 0.0006 and p < 0.0001). Schizophrenia patients between 65 and 80 years had a significantly higher risk of death than controls of the same age (+7.89%). schizophrenia patients younger than 55 years had more ICU admissions (+13.93%) and schizophrenia patients between 65 and 80 years and older than 80 years had less ICU admissions than controls of the same age (−15.44% and −5.93%, respectively). Our findings report the existence of disparities in health and health care between schizophrenia patients and patients without a diagnosis of severe mental illness. These disparities differed according to the age and clinical profile of schizophrenia patients, suggesting the importance of personalized COVID-19 clinical management and health care strategies before, during and after hospitalization for reducing health disparities in this vulnerable population. Published by Elsevier Masson SAS. 2021-04 2021-02-17 /pmc/articles/PMC7969983/ /pubmed/33753948 http://dx.doi.org/10.1016/j.amp.2021.02.016 Text en © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Communication
Fond, Guillaume
Llorca, Pierre-Michel
Lançon, Christophe
Auquier, Pascal
Boyer, Laurent
Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title_full Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title_fullStr Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title_full_unstemmed Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title_short Mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? COVID-19 et schizophrénie
title_sort mortalité dans la schizophrénie : vers un nouveau scandale sanitaire ? covid-19 et schizophrénie
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969983/
https://www.ncbi.nlm.nih.gov/pubmed/33753948
http://dx.doi.org/10.1016/j.amp.2021.02.016
work_keys_str_mv AT fondguillaume mortalitedanslaschizophrenieversunnouveauscandalesanitairecovid19etschizophrenie
AT llorcapierremichel mortalitedanslaschizophrenieversunnouveauscandalesanitairecovid19etschizophrenie
AT lanconchristophe mortalitedanslaschizophrenieversunnouveauscandalesanitairecovid19etschizophrenie
AT auquierpascal mortalitedanslaschizophrenieversunnouveauscandalesanitairecovid19etschizophrenie
AT boyerlaurent mortalitedanslaschizophrenieversunnouveauscandalesanitairecovid19etschizophrenie